Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "AAV-based gene therapy"

Complement Therapeutics Receives US FDA Clearance to Begin Opti-GAIN Phase-I/II Trial of CTx001 in Patients with GA Secondary to AMD

CTx001, an AAV-based gene therapy, delivers a mini-CR1 protein to modulate complement pathways and address Geographic Atrophy (GA), an advanced dry AMD causing irreversible vision loss.

AAV-based Gene Therapy | 09/10/2025 | By Dineshwori

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members